GoldenGolden
Advanced Search
Harmony Biosciences

Harmony Biosciences

Harmony Biosciences is a private biopharmaceutical company that develops and commercializes novel treatment options.

Harmony Biosciences is a private biopharmaceutical company in Pennsylvania that focuses on developing and commercializes novel treatment options. Founded in 2017 in Plymouth Meeting, Pennsylvania, United States by Bob Repella, Harmony Biosciences focuses on the central nervous system, including disorders of sleep and wakefulness. The company is currently working to advance the understanding of narcolepsy and provide information and resources to people who live with, and healthcare professionals who treat, this chronic, debilitating neurological disorder. The company's biopharmaceuticals focus on selective histamine 3 (H3) receptor antagonists for patients who are struggling with narcolepsy, enabling patients to recover quickly from central nervous system disorders.

The company’s product, WAKIX (pitolisant hydrochloride tablet, film coated), is a histamine-3 (H3) receptor antagonist/inverse agonist indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.

Timeline

January 27, 2020
Their latest funding was raised on Jan 27, 2020 from a Debt Financing round. Harmony Biosciences is funded by 9 investors. OrbiMed and CRG L.P. are the most recent investors. Harmony Biosciences is actively using 17 technologies for its website. These include Viewport Meta, IPhone / Mobile Compatible, and Google Analytics.
August 27, 2019
Harmony Biosciences has a post-money valuation in the range of $500M to $1B as of Aug 27, 2019 according to PrivCo.
2017
Founded

Funding rounds

People

Name
Role
LinkedIn

Andrew Serafin

Chief Business Officer

Bob Repella

CEO

John Jacobs

President, Chief Executive Officer & Member of the Board of Directors

Susan L Drexler

Chief Financial Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 18, 2021
BioSpace
Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, announced the appointment of John C. Jacobs, President and CEO of Harmony, to the Life Sciences Pennsylvania's Board of Directors, effective May 6, 2021.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.